A型肉毒毒素在瘢痕防治中的应用研究进展

余震; 任盼; 张晗; 陈辉; 马富鑫

doi:10.3760/cma.j.cn501120-20210208-00054

A型肉毒毒素在瘢痕防治中的应用研究进展

doi: 10.3760/cma.j.cn501120-20210208-00054

1.
西安市人民医院（西安市第四医院）医学美容与整形中心,西安　　710004
2.
空军军医大学第二附属医院整形烧伤科,西安　　710038

基金项目:

国家自然科学基金青年科学基金项目 81901980

陕西省重点研发计划 2021SF-107

详细信息

通讯作者:
马富鑫，Email：474210555@qq.com

计量
- 文章访问数: 310
- HTML全文浏览量: 101
- PDF下载量: 55
- 被引次数: 0
出版历程
- 收稿日期: 2021-02-08

Research advances on application of botulinum toxin type A in scar prevention and treatment

1.
The Plastic and Reconstructive Surgery Department of Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an 710004, China
2.
Department of Burns and Plastic Surgery, the Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China

Funds:

Youth Science Foundation Project of National Natural Science Foundation of China 81901980

Key Research and Development Planning Program of Shaanxi Province of China 2021SF-107

More Information

Corresponding author: Ma Fuxin, Email: 474210555@qq.com

摘要

摘要: 创面愈合的时间、创缘张力、成纤维细胞增殖和细胞外基质的沉积是瘢痕形成的重要原因，而A型肉毒毒素可在以上多个方面进行调控。A型肉毒毒素应用于瘢痕防治是近年来临床研究的热点之一。该文就国内外学者对A型肉毒毒素在瘢痕防治中的作用机制、临床应用及应用中产生的并发症和不良反应的相关研究进行简要综述。
- 肉毒杆菌毒素类，A型 /
- 瘢痕 /
- 成纤维细胞 /
- 细胞外基质
Abstract: The wound healing time, tension of wound edge, proliferation of fibroblast, and extracellular matrix deposition are the important factors of scar formation, and botulinum toxin type A can regulate the above. Prevention and treatment of scar with botulinum toxin type A is one of the hot topics of clinical research in recent years. This paper briefly reviews researches by scholars at home and abroad on the mechanism, clinical application, complications, and adverse effects of botulinum toxin type A in scar prevention and treatment.
- Botulinum toxins,type A /
- Cicatrix /
- Fibroblasts /
- Extracellular matrix
所有作者均声明不存在利益冲突

HTML全文

参考文献(45)

[1]	李旋, 席庆春, 方明松, 等. A型肉毒毒素在瘢痕疙瘩治疗中的机制和临床应用新进展[J].中国医疗美容,2020,10(1):114-117. DOI: 10.19593/j.issn.2095-0721.2020.01.029.
[2]	黎跃华, 刘佳琦, 肖丹, 等. A型肉毒毒素防治瘢痕的机制与临床应用研究进展[J].中华烧伤杂志,2017,33(4):254-256. DOI: 10.3760/cma.j.issn.1009-2587.2017.04.017.
[3]	SekiguchiA, MotegiSI, UchiyamaA, et al. Botulinum toxin B suppresses the pressure ulcer formation in cutaneous ischemia-reperfusion injury mouse model: possible regulation of oxidative and endoplasmic reticulum stress[J]. J Dermatol Sci, 2018,90(2):144-153. DOI: 10.1016/j.jdermsci.2018.01.006.
[4]	ShiY, LinH, CaoJ, et al. Botulinum toxin type A induces protective autophagy in human dermal microvascular endothelial cells exposed to an in vitro model of ischemia/reperfusion injury[J]. Exp Ther Med, 2018,16(6):4379-4386. DOI: 10.3892/etm.2018.6741.
[5]	ShiY, LinH, CaoJ, et al. Botulinum toxin type A attenuates apoptosis in human dermal microvascular endothelial cells exposed to an in vitro model of ischemia/reperfusion injury[J]. Transplant Proc, 2019,51(3):966-971. DOI: 10.1016/j.transproceed.2018.11.006.
[6]	UchiyamaA, YamadaK, PereraB, et al. Protective effect of botulinum toxin A after cutaneous ischemia-reperfusion injury[J]. Sci Rep, 2015,5:9072. DOI: 10.1038/srep09072.
[7]	JeongHS, LeeBH, SungHM, et al. Effect of botulinum toxin type A on differentiation of fibroblasts derived from scar tissue[J]. Plast Reconstr Surg, 2015,136(2):171e-178e. DOI: 10.1097/PRS.0000000000001438.
[8]	ScalaJ, VojvodicA, VojvodicP, et al. Botulin toxin use in scars/keloids treatment[J]. Open Access Maced J Med Sci, 2019,7(18):2979-2981. DOI: 10.3889/oamjms.2019.783.
[9]	ChenHC, YenCI, YangSY, et al. Reply: comparison of steroid and botulinum toxin type A monotherapy with combination therapy for treating human hypertrophic scars in an animal model[J]. Plast Reconstr Surg, 2018,141(3):452e-453e. DOI: 10.1097/PRS.0000000000004146.
[10]	SchaeferSM, GottschalkCH, JabbariB. Treatment of chronic migraine with focus on botulinum neurotoxins[J]. Toxins (Basel), 2015,7(7):2615-2628. DOI: 10.3390/toxins7072615.
[11]	Kasyanju CarreroLM, MaWW, LiuHF, et al. Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: updated review[J]. J Cosmet Dermatol, 2019,18(1):10-15. DOI: 10.1111/jocd.12828.
[12]	JablonkaEM, SherrisDA, GassnerHG. Botulinum toxin to minimize facial scarring[J]. Facial Plast Surg, 2012,28(5):525-535. DOI: 10.1055/s-0032-1325641.
[13]	SchlessingerJ, GilbertE, CohenJL, et al. New uses of AbobotulinumtoxinA in aesthetics[J]. Aesthet Surg J, 2017,37(Suppl 1):S45-58. DOI: 10.1093/asj/sjx005.
[14]	ChenM, YanT, MaK, et al. Botulinumtoxin type A inhibits α-smooth muscle actin and myosin II expression in fibroblasts derived from scar contracture[J]. Ann Plast Surg, 2016,77(3):e46-e49. DOI: 10.1097/SAP.0000000000000268.
[15]	KimYS, HongES, KimHS. Botulinum toxin in the field of dermatology: novel indications[J]. Toxins (Basel), 2017,9(12):403.DOI: 10.3390/toxins9120403.
[16]	周娜, 黎冬平, 罗彦竹, 等. 不同时期注射A型肉毒毒素对兔耳增生性瘢痕的影响[J].中国美容整形外科杂志,2021,32(3):182-186,后插4. DOI: 10.3969/j.issn.1673-7040.2021.03.015.
[17]	KimS, AhnM, PiaoY, et al. Effect of botulinum toxin type A on TGF-β/Smad pathway signaling: implications for silicone- induced capsule formation[J]. Plast Reconstr Surg, 2016,138(5):821e-829e. DOI: 10.1097/PRS.0000000000002625.
[18]	XiaoZ, ZhangM, LiuY, et al. Botulinum toxin type A inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar[J]. Aesthetic Plast Surg, 2011,35(5):802-807. DOI: 10.1007/s00266-011-9690-3.
[19]	AustinE, KooE, JagdeoJ. The cellular response of keloids and hypertrophic scars to botulinum toxin A: a comprehensive literature review[J]. Dermatol Surg, 2018,44(2):149-157. DOI: 10.1097/DSS.0000000000001360.
[20]	ShirakamiE, YamakawaS, HayashidaK. Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence[J/OL]. Burns Trauma,2020,8:tkz003[2022-03-22].https://pubmed.ncbi.nlm.nih.gov/32341924/.DOI: 10.1093/burnst/tkz003.
[21]	LeeSD, YiMH, KimDW, et al. The effect of botulinum neurotoxin type A on capsule formation around silicone implants: the in vivo and in vitro study[J]. Int Wound J, 2016,13(1):65-71. DOI: 10.1111/iwj.12228.
[22]	HaoR, LiZ, ChenX, et al. Efficacy and possible mechanisms of botulinum toxin type A on hypertrophic scarring[J]. J Cosmet Dermatol, 2018,17(3):340-346. DOI: 10.1111/jocd.12534.
[23]	KobayashiT, KimH, LiuX, et al. Matrix metalloproteinase-9 activates TGF-β and stimulates fibroblast contraction of collagen gels[J]. Am J Physiol Lung Cell Mol Physiol, 2014,306(11):L1006-1015. DOI: 10.1152/ajplung.00015.2014.
[24]	AlsterTS, HarrisonIS. Alternative clinical indications of botulinum toxin[J]. Am J Clin Dermatol, 2020,21(6):855-880. DOI: 10.1007/s40257-020-00532-0.
[25]	IbrahimO, KellerEC, ArndtKA. Update on botulinum neurotoxin use in aesthetic dermatology[J]. Semin Cutan Med Surg, 2014,33(4):152-156. DOI: 10.12788/j.sder.0115.
[26]	GassnerHG, SherrisDA. Chemoimmobilization: improving predictability in the treatment of facial scars[J]. Plast Reconstr Surg, 2003,112(5):1464-1466. DOI: 10.1097/01.PRS.0000081073.94689.DB.
[27]	WilsonAM. Use of botulinum toxin type A to prevent widening of facial scars[J]. Plast Reconstr Surg, 2006,117(6):1758-1766; discussion 1767-1768. DOI: 10.1097/01.prs.0000209944.45949.d1.
[28]	TollefsonTT, SendersCM, SykesJM, et al. Botulinum toxin to improve results in cleft lip repair[J]. Arch Facial Plast Surg, 2006,8(3):221-222. DOI: 10.1001/archfaci.8.3.221.
[29]	ChangCS, WallaceCG, HsiaoYC, et al. Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial[J]. PLoS One, 2014,9(12):e115690. DOI: 10.1371/journal.pone.0115690.
[30]	LeeSH, MinHJ, KimYW, et al. The efficacy and safety of early postoperative botulinum toxin A injection for facial scars[J]. Aesthetic Plast Surg, 2018,42(2):530-537. DOI: 10.1007/s00266-017-1008-7.
[31]	HuL, ZouY, ChangSJ, et al. Effects of botulinum toxin on improving facial surgical scars: a prospective, split-scar, double-blind, randomized controlled trial[J]. Plast Reconstr Surg, 2018,141(3):646-650. DOI: 10.1097/PRS.0000000000004110.
[32]	KimYS, LeeHJ, ChoSH, et al. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial[J]. Wound Repair Regen, 2014,22(5):605-612. DOI: 10.1111/wrr.12204.
[33]	LiYH, YangJ, LiuJQ, et al. A randomized, placebo-controlled, double-blind, prospective clinical trial of botulinum toxin type A in prevention of hypertrophic scar development in median sternotomy wound[J]. Aesthetic Plast Surg, 2018,42(5):1364- 1369. DOI: 10.1007/s00266-018-1187-x.
[34]	AbediniR, Mehdizade RayeniN, Haddady AbianehS, et al. Botulinum toxin type A injection for mammoplasty and abdominoplasty scar management: a split-scar double-blinded randomized controlled study[J]. Aesthetic Plast Surg, 2020,44(6):2270-2276. DOI: 10.1007/s00266-020-01916-7.
[35]	ZhangDZ, LiuXY, XiaoWL, et al. Botulinum toxin type A and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta-analysis of randomized controlled trials[J]. PLoS One, 2016,11(3):e0151627. DOI: 10.1371/journal.pone.0151627.
[36]	WangY, WangJ, ZhangJ, et al. Effectiveness and safety of botulinum toxin type A injection for scar prevention: a systematic review and meta-analysis[J]. Aesthetic Plast Surg, 2019,43(5):1241-1249. DOI: 10.1007/s00266-019-01358-w.
[37]	YangW, LiG. The safety and efficacy of botulinum toxin type A injection for postoperative scar prevention: a systematic review and meta-analysis[J]. J Cosmet Dermatol, 2020,19(4):799-808. DOI: 10.1111/jocd.13139.
[38]	AnMK, ChoEB, ParkEJ, et al. Appropriate timing of early postoperative botulinum toxin type A injection for thyroidectomy scar management: a split-scar study[J]. Plast Reconstr Surg, 2019,144(4):659e-668e. DOI: 10.1097/PRS.0000000000006064.
[39]	ÇalıskanE, GamsızkanM, AçıkgözG, et al. Intralesional treatments for hypertrophic scars: comparison among corticosteroid, 5-fluorouracil and botulinum toxin in rabbit ear hypertrophic scar model[J]. Eur Rev Med Pharmacol Sci, 2016,20(8):1603-1608.
[40]	GauglitzGG, BureikD, DombrowskiY, et al. Botulinum toxin A for the treatment of keloids[J]. Skin Pharmacol Physiol, 2012,25(6):313-318. DOI: 10.1159/000342125.
[41]	胡太平, 陶剑光, 周丽娟, 等. CO2点阵激光联合复方倍他米松和A型肉毒素治疗增生性瘢痕的临床研究[J].中国激光医学杂志,2020,29(4):181-187. DOI: 10.13480/j.issn1003-9430.2020.0181.
[42]	HuangSH, WuKW, LoJJ, et al. Synergic effect of botulinum toxin type-A and triamcinolone alleviates scar pruritus by modulating epidermal hyperinnervation: a preliminary report[J/OL].Aesthet Surg J, 2021:sjab105[2021-05-07]. https://academic.oup.com/asj/advance-article/doi/ 10.1093/asj/sjab105/6154581#.DOI: 10.1093/asj/sjab105.
[43]	GiordanoCN, MatarassoSL, OzogDM. Injectable and topical neurotoxins in dermatology: indications, adverse events, and controversies[J]. J Am Acad Dermatol, 2017,76(6):1027-1042. DOI: 10.1016/j.jaad.2016.11.012.
[44]	JiaZ, LuH, YangX, et al. Adverse events of botulinum toxin type A in facial rejuvenation: a systematic review and meta-analysis[J]. Aesthetic Plast Surg, 2016,40(5):769-777. DOI: 10.1007/s00266-016-0682-1.
[45]	中国整形美容协会瘢痕医学分会.瘢痕早期治疗全国专家共识(2020版)[J].中华烧伤杂志,2021,37(2):113-125.DOI: 10.3760/cma.j.cn501120-20200609-00300.